DiscoveRx has acquired BioSeek, a drug discovery services company based in South San Francisco, CA. BioSeek’s phenotypic screening technology aims to improve the success rate of R&D by integrating primary cell profiling into the drug discovery process. The BioMAP systems incorporate primary human cell-based disease models that generate predictive biological activity profiles for potential drugs. Financial terms were not disclosed.
 
“The integration of BioSeek provides two new capabilities to DiscoveRx Corporation,” said Pyare L. Khanna, president and chief executive officer of DiscoveRx Corp. “Expertise in primary cell disease models as well as a highly differentiated compound characterization service. These new capabilities further strengthen our position as a premier drug discovery solution provider that develops and commercializes high-value products and specialized services.”
 
“BioSeek has become an integral part of the pharmaceutical industry’s drug discovery programs, and in joining DiscoveRx, it will gain the opportunity to expand the utility of BioMAP technology platform even further,” said Jack Davis, chairman and chief executive officer of Asterand. BioSeek was formerly part of the Asterand Company.